Bellicum Pharmaceuticals, Inc. BLCM today announced the presentation of interim data from the
lead site in the ongoing BP-004 Phase 1/2 clinical trial during the 57th
Annual Meeting of the American Society of Hematology (ASH) in Orlando,
Florida. Pediatric patients in the study with a variety of genetic
diseases achieved disease-free outcomes following a haploidentical, T
cell-depleted hematopoietic stem cell transplant (HSCT) followed by an
add-back of BPX-501 donor T cells. The study is designed to evaluate
whether this regimen is safe and improves immune reconstitution,
infection control and overall outcomes.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in